New injection after liver ablation may stop colorectal cancer spread
NCT ID NCT07321847
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests whether an injectable drug called IP-001, given right after standard heat-based liver tumor ablation, can help prevent colorectal cancer from coming back in the liver or spreading elsewhere. About 717 adults with colorectal cancer that has spread only to the liver will be randomly assigned to receive either ablation alone or ablation plus a low or high dose of IP-001. The goal is to see if the drug can activate the immune system to fight any remaining cancer cells and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Conditions
Explore the condition pages connected to this study.